Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future.

Literature DB >> 30652096

The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future.

Carlo Sposito¹, Vincenzo Mazzaferro^1,2.

Abstract

Entities: Chemical Disease Species

Year: 2018 PMID： 30652096 PMCID： PMC6295389 DOI： 10.21037/hbsn.2018.10.06

Source DB: PubMed Journal: Hepatobiliary Surg Nutr ISSN： 2304-3881 Impact factor: 7.293

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

Review 1. Current locoregional therapies and treatment strategies in hepatocellular carcinoma.

Authors: L Cardarelli-Leite; A Hadjivassiliou; D Klass; J Chung; S G F Ho; H J Lim; P T W Kim; A Mujoomdar; D M Liu
Journal: Curr Oncol Date: 2020-11-01 Impact factor: 3.677

Review 2. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors: Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal: Nat Rev Gastroenterol Hepatol Date: 2021-01-28 Impact factor: 46.802

3. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation.

Authors: Sandi A Kwee; Linda L Wong; Miles M Sato; Jared D Acoba; Young Soo Rho; Avantika Srivastava; Douglas P Landsittel
Journal: J Vasc Interv Radiol Date: 2021-07-07 Impact factor: 3.682

4. Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study.

Authors: Thomas Helmberger; Dirk Arnold; José I Bilbao; Niels de Jong; Geert Maleux; Anders Nordlund; Bora Peynircioglu; Bruno Sangro; Ricky A Sharma; Agnes Walk
Journal: JMIR Res Protoc Date: 2020-04-22

Review 5. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.

Authors: Mina S Makary; Stuart Ramsell; Eric Miller; Eliza W Beal; Joshua D Dowell
Journal: World J Gastroenterol Date: 2021-11-21 Impact factor: 5.742

Review 6. Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization.

Authors: Richard F Pollock; Fabien Colaone; Suki Shergill; Victoria K Brennan; Ion Agirrezabal
Journal: Clinicoecon Outcomes Res Date: 2021-09-22

7. Radioembolization of Hepatocellular Carcinoma with ⁹⁰Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods.

Authors: Chiara Romanò; Stefania Mazzaglia; Marco Maccauro; Carlo Spreafico; Alejandro Gabutti; Gabriele Maffi; Carlo Morosi; Tommaso Cascella; Marta Mira; Maria Chiara De Nile; Gianluca Aliberti; Giovanni Argiroffi; Valentina Fuoco; Sherrie Bhoori; Consuelo Zanette; Alfonso Marchianò; Ettore Seregni; Vincenzo Mazzaferro; Carlo Chiesa
Journal: Cancers (Basel) Date: 2022-02-15 Impact factor: 6.639

The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future.

Review 1. Current locoregional therapies and treatment strategies in hepatocellular carcinoma.

Review 2. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

3. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation.

4. Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study.

Review 5. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.

Review 6. Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization.

7. Radioembolization of Hepatocellular Carcinoma with ⁹⁰Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods.

8. Expression and Prognostic Role of E2F2 in Hepatocellular Carcinoma.

Review 9. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update.

Review 10. New Radionuclides and Technological Advances in SPECT and PET Scanners.

The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future.

Review 1. Current locoregional therapies and treatment strategies in hepatocellular carcinoma.

Review 2. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

3. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation.

4. Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study.

Review 5. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.

Review 6. Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization.

7. Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods.

8. Expression and Prognostic Role of E2F2 in Hepatocellular Carcinoma.

Review 9. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update.

Review 10. New Radionuclides and Technological Advances in SPECT and PET Scanners.

7. Radioembolization of Hepatocellular Carcinoma with ⁹⁰Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods.